Evidence map›Paper›PMID 23856624›Full record

ArticleAIDS (London, England)2013

HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype.

Jennifer Mabuka, Leslie Goo, Maxwel M Omenda, Ruth Nduati, Julie Overbaugh

Abstract read
In one paragraph

Article in AIDS (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Classification and Design of HIV-1 Integrase Inhibitors Based on Machine Learning.Computational and mathematical methods in medicine · 2021
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Jennifer MabukaDivision of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Leslie Goo
Maxwel M Omenda
Ruth Nduati
Julie Overbaugh
University of Washington · USCancer Research Center · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAUniversity of Nairobi · KE

Funding

INTERNATIONAL TRAINING GRANT IN EPIDEMIOLOGYD43TW000007 · FIC · UNIVERSITY OF WASHINGTON · PI FARQUHAR, CAREY · 1988 to 2012
$16.3M
THE ROLE OF ANTIBODIES IN MOTHER TO CHILD HIV TRANSMISSIONR01AI076105 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 2008 to 2023
$8.8M
CHARACTERIZATION OF HIV-1 ANTIBODY RESPONSES IN CHRONICALLY INFECTED WOMENR01AI103981 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 2012 to 2015
$2.8M
CLINICAL AND MOLECULAR STUDIES OF DRUG-RESISTANT MALARIAK01TW000007 · FIC · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI DORSEY, MATTHEW G · 1999 to 2005
$513k
FIC NIH HHS D43 TW000007FIC NIH HHS D43-TW000007FIC NIH HHS K01 TW000007NIAID NIH HHS AI076105NIAID NIH HHS R01 AI076105NIAID NIH HHS R01 AI103981
6 · The paper itself

Abstract

rationaleTo protect against HIV infection, passively transferred and/or vaccine-elicited neutralizing antibodies (NAbs) need to effectively target diverse subtypes that are transmitted globally. These variants are a limited subset of those present during chronic infection and display some unique features. In the case of mother-to-child transmission (MTCT), transmitted variants tend to be resistant to neutralization by maternal autologous NAbs.

methodTo investigate whether variants transmitted during MTCT are generally resistant to HIV-1-specific NAbs, 107 maternal or infant variants representing the dominant HIV-1 subtypes were tested against six recently identified HIV-1-specific broadly neutralizing monoclonal antibodies (bNAbs), NIH45-46W, VRC01, PGT128, PGT121, PG9 and PGT145.

resultsInfant and maternal variants did not differ in their neutralization sensitivity to individual bNAbs, nor did viruses from transmitting versus nontransmitting mothers, although there was a trend for viruses from transmitting mothers to be less sensitive overall. No single bNAb neutralized all viruses, but a combination of bNAbs that target distinct epitopes covered 100% of the variants tested. Compared with heterosexually transmitted variants, vertically transmitted variants were significantly more sensitive to neutralization by PGT128 and PGT121 (P=0.03 in both cases), but there were no differences for the other bNAbs. Overall, subtype A variants were significantly more sensitive to NIH45-46 (P=0.04), VRC01 (P=0.002) and PGT145 (P=0.03) compared with the nonsubtype A and less sensitive to PGT121 than subtype Cs (P=0.0001).

conclusionA combination of bNAbs against distinct epitopes may be needed to provide maximum coverage against viruses in different modes of transmission and diverse subtypes.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingFemaleHIV-1HIV AntibodiesHIV InfectionsHumansInfantInfectious Disease Transmission, VerticalNeutralization TestsAntibodies, MonoclonalAntibodies, NeutralizingHIV Antibodies

Identifiers

PMID23856624
PMCPMC4080909
OpenAlexW2036549279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.